Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM

Cytokine

Volumn 57, Issue 2, 2012, Pages 300-303

  Wang, Bo ^a   Yang, Gangyi ^a   Yang, Mengliu ^a   Liao, Yong ^b   Li, Zhiyong ^a   Boden, Guenther ^c   Li, Ling ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Chongqing Corps Hospital of Chinese People's Armed Police Forces   (China)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibroblast growth factor 21; Mitiglinide; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; FATTY ACID; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITIGLINIDE; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BLOOD LEVEL; BODY FAT; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; WAIST HIP RATIO;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; ISOINDOLES; MALE; MIDDLE AGED;

EID: 84855446766     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.11.002     Document Type: Article

References (20)

1. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C., Chen Y., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
2. Fisher F.M., Chui P.C., Antonellis P.J., Bina H.A., Kharitonenkov A., Flier J.S., et al. Obesity is a fibroblast growth factor 21 (FGF-21)-resistant state. Diabetes 2010, 59:2781-2789.
3. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
4. Sarruf D.A., Thaler J.P., Morton G.J., German J., Fischer J.D., Ogimoto K., et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010, 59:1817-1824.
5. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
6. Coskun T., Bina H.A., Schneider M.A., Dunbar J.D., Hu C.C. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
7. Uonaga T., Toyoda K., Okitsu T., Zhuang X., Yamane S., Uemoto S., et al. FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model. Islets 2010, 2:247-251.
8. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115:1627-1635.
9. Badman M.K., Koester A., Flier J.S., Kharitonenkov A., Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009, 150:4931-4940.
10. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.G., Liu F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
11. Dostalova I., Kavalkova P., Haluzikova D., Lacinova Z., Mraz M., Papezova H., et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008, 93:3627-3632.
12. Sato Y., Nishikawa M., Shinkai H., Sukegawa E. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)- carbonyl] -D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 1991, 12:53-59.
13. Ohnota H., Koizumi T., Tsutsumi N., Kobayashi M., Inoue S., Sato F. Novel rapid- and short-acting hypoglycemic agent, a calcium (2s)-2-benzyl-3-(cishexahydro-2-isoindolinylcarbonyl) propionate (KAD- 1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. JPharmacol Exp Ther 1994, 269:489-495.
14. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Med 1998, 15:539-553.
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
16. Sánchez J., Palou A., Pico C. Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction. Endocrinology 2009, 150:5341-5350.
17. Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., Defronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009, 32:1542-1546.
18. Mai K., Andres J., Biedasek K., Weicht J., Bobbert T., Sabath M., et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009, 58:1532-1538.
19. Shigeto M., Katsura M., Matsuda M., Ohkuma S., Kaku K. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. JPET 2007, 322:1-7.
20. Xin G., Zhimin L., Guangwei L., Juming L., Yingsheng Z., Mingcai Q. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in china. J Inter Med Res 2009, 37:812-821.